

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 6, 2024

Consolidated Financial Results
for the First Six Months of the Fiscal Year Ending March 31, 2025
(Under Japanese GAAP)

Listed Company: Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: Tokyo Stock Exchange)

Code Number: 4559

(URL: <https://www.zeria.co.jp/english/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date to submit the Semi-annual Securities Report: November 8, 2024

Scheduled date to commence dividend payments: December 2, 2024

Preparation of supplementary documents to the financial results: Yes

Holding of financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2024 through September 30, 2024)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended								
September 30, 2024	42,422	15.7	6,459	21.2	7,949	44.6	6,061	12.3
September 30, 2023	36,678	8.8	5,327	(9.6)	5,495	6.1	5,396	35.0

Note: Comprehensive income: For the six months ended September 30, 2024: 9,709 million yen [(13.7)%]

For the six months ended September 30, 2023: 11,254 million yen [39.5%]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended		
September 30, 2024	137.51	–
September 30, 2023	122.43	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
As of			
September 30, 2024	158,339	88,567	55.7
March 31, 2024	150,533	79,828	52.9

Reference: Equity: As of September 30, 2024: 88,268 million yen

As of March 31, 2024: 79,622 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended					
March 31, 2024	–	22.00	–	22.00	44.00
Year ending					
March 31, 2025	–	23.00			
Year ending					
March 31, 2025 (Forecast)			–	23.00	46.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2025 (April 1, 2024 through March 31, 2025)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	86,000	13.6	11,000	14.3	11,000	29.2	8,500	9.9	192.83

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the semi-annual consolidated financial statements: Yes

Note: For details, please refer to “2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to semi-annual consolidated financial statements (Notes on special accounting methods for preparation of semi-annual consolidated financial statements)” on page 10 of the Attached Material.

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

Note: For details, please refer to “2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to semi-annual consolidated financial statements (Notes on change in accounting policy)” on page 10 of the Attached Material.

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):

As of September 30, 2024: 53,119,190 shares As of March 31, 2024: 53,119,190 shares

2) Number of shares of treasury shares as of the end of the term:

As of September 30, 2024: 9,039,651 shares As of March 31, 2024: 9,039,354 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the six months ended September 30, 2024: 44,079,667 shares

For the six months ended September 30, 2023: 44,080,153 shares

* Semi-annual results reports are exempt from review conducted by certified public accountants or an audit corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors. For the assumptions made in financial forecasts and cautions concerning the use thereof, please refer to “1. Summary of Business Results (3) Explanation of consolidated financial forecasts and other forward-looking statements” on page 4 of the Attached Material.

○ **Table of contents of attachments**

1. Summary of Business Results	2
(1) Summary of business results for the semi-annual period under review	2
(2) Overview of financial position for the semi-annual period under review	2
(3) Explanation of consolidated financial forecasts and other forward-looking statements	4
2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto	5
(1) Semi-annual consolidated balance sheet	5
(2) Semi-annual consolidated statement of income and semi-annual consolidated statement of comprehensive income	7
Semi-annual consolidated statement of income	7
Semi-annual consolidated statement of comprehensive income	8
(3) Semi-annual consolidated statement of cash flows	9
(4) Notes to semi-annual consolidated financial statements	10
(Notes on change in accounting policy)	10
(Notes on special accounting methods for preparation of semi-annual consolidated financial statements)	10
(Notes on segment information, etc.)	11
(Notes on significant changes in the amount of shareholders' equity)	12
(Notes on premise of a going concern)	12
3. Supplemental Information	13
(1) Sales of major products and merchandise Consolidated	13
(2) Status of pipeline of new drugs	14

1. Summary of Business Results

(1) Summary of business results for the semi-annual period under review

Net sales for the first six months of the fiscal year ending March 31, 2025 were 42,422 million yen (up 15.7% from the same period of the previous fiscal year). As for profits, operating profit was 6,459 million yen (up 21.2% from the same period of the previous fiscal year), ordinary profit was 7,949 million yen (up 44.6% from the same period of the previous fiscal year), and profit attributable to owners of parent was 6,061 million yen (up 12.3% from the same period of the previous fiscal year). Among other factors, the increases in ordinary profit and below were due to an increase in sales and large foreign exchange gains resulting from the depreciation of the Swiss franc against the euro, British pound and other European currencies.

Below are the results by business segment.

(i) *Ethical Pharmaceuticals Business*

As for our mainstay product, Asacol, a therapeutic agent for ulcerative colitis, sales in the domestic market faced challenging circumstances, owing to the NHI price revision implemented in April 2024. Despite this, sales increased overall as a result of strong sales in overseas markets, including Northern Europe, and the impact of foreign exchange rates. DIFICLIR (domestic sales name: Dafclir) achieved a significant sales growth in France, Germany, the UK, and other countries. Sales of Entocort (domestic sales name: Zentacort), an inflammatory bowel disease therapeutic agent, increased partly due to strong sales in Canada and positive impacts from foreign exchange rates. Sales of Acofide, a drug for functional dyspepsia, were almost on a par with the previous fiscal year. In September 2024, we received domestic approval for the manufacture and marketing of Veltassa for the therapeutic agent of hyperkalemia, and we are moving forward with preparations for the start of sales.

As a result, net sales in the business amounted to 28,544 million yen (up 19.4% from the same period of the previous fiscal year).

(ii) *Consumer Healthcare Business*

As for the Hepalyse range, our mainstay product, sales increased for both the pharmaceutical Hepalyse range and the Hepalyse W range for convenience stores. In addition, both the WithOne range of botanical laxative products, as well as the Prevaline range of dermatosis treatments, including Prevaline α Quick Ointment and Prevaline α Quick Cream, which were launched last year, performed well. The Chondroitin range was almost on a par with the previous fiscal year. Moreover, shipments began in September 2024 for Hepalyse W Shine, which was launched in October as a new product in the Hepalyse W series.

As a result, net sales in the business amounted to 13,802 million yen (up 8.7% from the same period of the previous fiscal year).

(iii) *Other*

Net sales in this segment amounted to 75 million yen (down 1.9% from the same period of the previous fiscal year), mainly due to insurance agency business and real estate lease revenue.

(2) Overview of financial position for the semi-annual period under review

(i) Assets, liabilities, and net assets

Total assets at the end of the semi-annual period of the fiscal year ending March 31, 2025 were 158,339 million yen, an increase of 7,806 million yen from the end of the previous fiscal year. Current assets increased 6,835 million yen to 64,644 million yen from the end of the previous fiscal year, and non-current assets increased 970 million yen to 93,695 million yen from the end of the previous fiscal year. Major changes in current assets included an increase of 4,037 million yen in cash and deposits and an

increase of 2,638 million yen in notes and accounts receivable - trade. Main changes in non-current assets were an increase of 1,147 million yen in intangible assets.

Total liabilities at the end of the semi-annual period under review were 69,771 million yen, a decrease of 932 million yen from the end of the previous fiscal year. Current liabilities decreased 468 million yen to 54,050 million yen from the end of the previous fiscal year, and non-current liabilities decreased 464 million yen to 15,721 million yen from the end of the previous fiscal year. The changes in current liabilities were an increase of 534 million yen in accounts payable - trade, a decrease of 3,102 million yen in short-term borrowings, an increase of 1,430 million yen in income taxes payable, a decrease of 431 million yen in provision for bonuses, and an increase of 1,100 million yen in other of current liabilities, including an increase in accrued expenses. Main change in non-current liabilities was a decrease of 607 million yen in long-term borrowings.

Net assets at the end of the semi-annual period under review were 88,567 million yen, an increase of 8,739 million yen from the end of the previous fiscal year. This was mainly due to profit attributable to owners of parent of 6,061 million yen, payment of 969 million yen as dividends declared at the end of the previous period, and an increase of 4,001 million yen in foreign currency translation adjustment.

As a result, the equity ratio at the end of the semi-annual period under review increased by 2.8% from the end of the previous fiscal year to 55.7%.

(ii) Status of cash flows

Cash and cash equivalents (below, "cash") at the end of the semi-annual period under review increased 3,564 million yen from the beginning of the period to 22,168 million yen. This was mainly due to net cash provided by operating activities of 8,695 million yen, despite net cash used in investing activities of 1,146 million yen and net cash used in financing activities of 5,130 million yen.

The status of each cash flow and its factors for the semi-annual period under review are as follows.

[Net cash provided by (used in) operating activities]

Net cash provided by operating activities amounted to 8,695 million yen in the semi-annual period under review (up 3,730 million yen from the same period of the previous fiscal year). This was mainly due to profit before income taxes of 7,751 million yen, depreciation of 3,386 million yen, and an increase in trade receivables of 1,667 million yen.

[Net cash provided by (used in) investing activities]

Net cash used in investing activities totaled 1,146 million yen in the semi-annual period under review (up 1,040 million yen from the same period of the previous fiscal year). This was mainly due to payments into time deposits of 430 million yen and purchase of property, plant and equipment of 732 million yen.

[Net cash provided by (used in) financing activities]

Net cash used in financing activities totaled 5,130 million yen in the semi-annual period under review (down 2,845 million yen from the same period of the previous fiscal year). This was mainly due to a decrease of 928 million yen in short-term borrowings, proceeds from long-term borrowings of 1,000 million yen, repayments of long-term borrowings of 4,039 million yen, and dividends paid of 965 million yen.

(3) Explanation of consolidated financial forecasts and other forward-looking statements

In line with performance trends in the semi-annual period under review, we have revised the full-year consolidated financial forecasts for the fiscal year ending March 31, 2025, which were first announced on May 9, 2024. For more details, please see the Notice Regarding Revisions to Financial Forecasts announced on November 5, 2024 (Japanese version only).

2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto

(1) Semi-annual consolidated balance sheet

(Thousands of yen)

	As of March 31, 2024	As of September 30, 2024
Assets		
Current assets		
Cash and deposits	20,323,724	24,360,950
Notes and accounts receivable - trade	21,249,302	23,887,945
Merchandise and finished goods	7,569,173	7,996,409
Work in process	1,842,077	2,146,182
Raw materials and supplies	5,078,508	4,893,344
Other	1,915,485	1,519,339
Allowance for doubtful accounts	(169,241)	(159,675)
Total current assets	57,809,029	64,644,495
Non-current assets		
Property, plant and equipment		
Buildings, net	6,607,334	6,470,815
Land	12,581,849	12,589,472
Other, net	7,328,652	7,737,703
Total property, plant and equipment	26,517,836	26,797,991
Intangible assets		
Goodwill	4,262,818	4,039,560
Sales right	29,496,467	30,633,074
Other	9,380,420	9,614,991
Total intangible assets	43,139,706	44,287,626
Investments and other assets		
Investment securities	9,145,154	8,796,893
Retirement benefit asset	13,410,761	13,274,991
Other	552,538	570,798
Allowance for doubtful accounts	(41,433)	(33,034)
Total investments and other assets	23,067,020	22,609,648
Total non-current assets	92,724,563	93,695,266
Total assets	150,533,593	158,339,762
Liabilities		
Current liabilities		
Accounts payable - trade	3,273,950	3,808,933
Short-term borrowings	38,283,719	35,180,934
Income taxes payable	1,967,210	3,398,017
Provision for bonuses	1,584,737	1,153,488
Other	9,408,853	10,508,938
Total current liabilities	54,518,471	54,050,312
Non-current liabilities		
Long-term borrowings	7,943,800	7,335,850
Retirement benefit liability	458,109	507,167
Asset retirement obligations	56,239	56,345
Other	7,728,181	7,822,245
Total non-current liabilities	16,186,329	15,721,607
Total liabilities	70,704,801	69,771,920

(Thousands of yen)

	As of March 31, 2024	As of September 30, 2024
Net assets		
Shareholders' equity		
Share capital	6,593,398	6,593,398
Capital surplus	11,685,121	11,685,121
Retained earnings	59,254,325	64,345,849
Treasury shares	(18,265,810)	(18,266,437)
Total shareholders' equity	59,267,035	64,357,933
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2,001,571	1,905,373
Foreign currency translation adjustment	14,660,305	18,661,835
Remeasurements of defined benefit plans	3,693,650	3,342,907
Total accumulated other comprehensive income	20,355,527	23,910,117
Non-controlling interests	206,229	299,791
Total net assets	79,828,792	88,567,842
Total liabilities and net assets	150,533,593	158,339,762

(2) Semi-annual consolidated statement of income and semi-annual consolidated statement of comprehensive income

Semi-annual consolidated statement of income

(Thousands of yen)

	Six months ended September 30, 2023	Six months ended September 30, 2024
Net sales	36,678,404	42,422,617
Cost of sales	9,631,957	11,409,066
Gross profit	27,046,446	31,013,551
Selling, general and administrative expenses	21,719,007	24,554,334
Operating profit	5,327,439	6,459,216
Non-operating income		
Interest income	46,176	120,528
Dividend income	192,672	225,858
Foreign exchange gains	1,017	1,320,978
Recoveries of written off receivables	89,761	–
Other	77,461	124,229
Total non-operating income	407,090	1,791,596
Non-operating expenses		
Interest expenses	226,110	232,249
Other	12,481	69,188
Total non-operating expenses	238,591	301,438
Ordinary profit	5,495,938	7,949,373
Extraordinary income		
Gain on sale of non-current assets	–	2,903
Gain on sale of investment securities	0	–
Reversal of provision for loss on cancellation of contracts	923,331	–
Total extraordinary income	923,332	2,903
Extraordinary losses		
Loss on retirement of non-current assets	6,336	3,864
Loss on valuation of investment securities	–	196,543
Total extraordinary losses	6,336	200,407
Profit before income taxes	6,412,933	7,751,869
Income taxes	1,005,062	1,625,522
Profit	5,407,870	6,126,346
Profit attributable to non-controlling interests	11,093	65,065
Profit attributable to owners of parent	5,396,776	6,061,280

Semi-annual consolidated statement of comprehensive income

(Thousands of yen)

	Six months ended September 30, 2023	Six months ended September 30, 2024
Profit	5,407,870	6,126,346
Other comprehensive income		
Valuation difference on available-for-sale securities	1,264,461	(96,198)
Foreign currency translation adjustment	4,844,478	4,030,007
Remeasurements of defined benefit plans, net of tax	(262,732)	(350,742)
Total other comprehensive income	5,846,207	3,583,067
Comprehensive income	11,254,078	9,709,413
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	11,223,314	9,615,870
Comprehensive income attributable to non-controlling interests	30,764	93,542

(3) Semi-annual consolidated statement of cash flows

(Thousands of yen)

	Six months ended September 30, 2023	Six months ended September 30, 2024
Cash flows from operating activities		
Profit before income taxes	6,412,933	7,751,869
Depreciation	3,031,173	3,386,993
Amortization of goodwill	363,836	356,214
Increase (decrease) in provision for bonuses	(562,105)	(468,042)
Increase (decrease) in provision for loss on cancellation of contracts	(923,331)	–
Increase (decrease) in retirement benefit liability	(17,638)	32,285
Interest and dividend income	(238,849)	(346,387)
Interest expenses	226,110	232,249
Foreign exchange losses (gains)	(204,736)	(436,150)
Loss (gain) on valuation of investment securities	–	196,543
Decrease (increase) in trade receivables	(2,804,465)	(1,667,082)
Decrease (increase) in inventories	(824,917)	(93,461)
Increase (decrease) in trade payables	1,034,301	344,542
Decrease (increase) in other current assets	(74,785)	(66,069)
Increase (decrease) in other current liabilities	549,034	110,575
Decrease (increase) in retirement benefit asset	(493,330)	(413,269)
Other, net	(82,137)	18,212
Subtotal	5,391,092	8,939,022
Interest and dividends received	238,593	346,377
Interest paid	(216,497)	(255,680)
Income taxes paid	(448,416)	(334,569)
Net cash provided by (used in) operating activities	4,964,771	8,695,150
Cash flows from investing activities		
Payments into time deposits	(125,000)	(430,577)
Proceeds from withdrawal of time deposits	125,000	125,000
Purchase of property, plant and equipment	(1,395,136)	(732,099)
Purchase of intangible assets	(888,433)	(116,966)
Other, net	97,003	8,391
Net cash provided by (used in) investing activities	(2,186,567)	(1,146,251)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	1,168,875	(928,550)
Proceeds from long-term borrowings	500,000	1,000,000
Repayments of long-term borrowings	(2,824,420)	(4,039,090)
Repayments of lease liabilities	(160,870)	(196,698)
Purchase of treasury shares	(323)	(626)
Dividends paid	(966,355)	(965,969)
Dividends paid to non-controlling interests	(2,308)	–
Net cash provided by (used in) financing activities	(2,285,403)	(5,130,935)
Effect of exchange rate change on cash and cash equivalents	1,756,142	1,146,622
Net increase (decrease) in cash and cash equivalents	2,248,943	3,564,586
Cash and cash equivalents at beginning of period	16,094,078	18,604,144
Cash and cash equivalents at end of period	18,343,022	22,168,731

(4) Notes to semi-annual consolidated financial statements

(Notes on change in accounting policy)

Application of the “Accounting Standard for Current Income Taxes” and other relevant ASBJ regulations

The Company has applied the “Accounting Standard for Current Income Taxes” (Accounting Standards Board of Japan (ASBJ) Statement No. 27, October 28, 2022; the “Revised Accounting Standard of 2022”) and other relevant ASBJ regulations from the beginning of the semi-annual period under review.

Revisions to categories for recording current income taxes (taxation on other comprehensive income) conform to the transitional treatment in the proviso of paragraph 20-3 of the Revised Accounting Standard of 2022 and to the transitional treatment in the proviso of paragraph 65-2(2) of the Guidance on Accounting Standard for Tax Effect Accounting (ASBJ Guidance No. 28, October 28, 2022; hereinafter, the “Revised Application Guidance of 2022”). This change has no impact on the semi-annual consolidated financial statements.

In addition, for revisions related to the review of the treatment in consolidated financial statements when a gain or loss on sale arising from the sale of shares of subsidiaries, etc. among consolidated companies is deferred for tax purposes, the Company has applied the Revised Application Guidance of 2022 from the beginning of the semi-annual period under review. The change in accounting policy has been applied retrospectively, and the semi-annual consolidated financial statements and consolidated financial statements for the same period of the previous fiscal year and for the previous fiscal year have been prepared on a retrospective basis. This change has no impact on the semi-annual consolidated financial statements and consolidated financial statements for the same period of the previous fiscal year and for the previous fiscal year.

(Notes on special accounting methods for preparation of semi-annual consolidated financial statements)

Calculation of tax expenses

Tax expenses were calculated by reasonably estimating the effective tax rate after applying tax effect accounting to the profit before income taxes for the fiscal year that includes the semi-annual period of the current fiscal year and multiplying profit before income taxes by such estimated effective tax rate.

(Notes on segment information, etc.)

[Segment information]

I First six months of the previous fiscal year (April 1, 2023 to September 30, 2023)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in semi-annual consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	23,900,997	12,700,282	36,601,280	77,124	36,678,404	–	36,678,404
Intersegment sales and transfers	2,958	62	3,020	320,078	323,099	(323,099)	–
Total	23,903,955	12,700,344	36,604,300	397,202	37,001,503	(323,099)	36,678,404
Segment profit	5,257,968	2,526,140	7,784,109	124,092	7,908,202	(2,580,762)	5,327,439

(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (2,580,762) thousand yen is mainly corporate expenses, such as general and administrative expenses that are not allocated to reportable segments.
3. Segment profit is adjusted with operating profit in the semi-annual consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment
Not applicable.

II First six months of the current fiscal year (April 1, 2024 to September 30, 2024)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in semi-annual consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	28,544,724	13,802,248	42,346,972	75,645	42,422,617	–	42,422,617
Intersegment sales and transfers	5,457	64	5,521	300,214	305,736	(305,736)	–
Total	28,550,181	13,802,313	42,352,494	375,859	42,728,354	(305,736)	42,422,617
Segment profit	5,830,595	3,121,985	8,952,580	118,312	9,070,892	(2,611,676)	6,459,216

(Notes) 1. “Other” is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (2,611,676) thousand yen is mainly corporate expenses, such as general and administrative expenses that are not allocated to reportable segments.
3. Segment profit is adjusted with operating profit in the semi-annual consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment
Not applicable.

(Notes on significant changes in the amount of shareholders' equity)

Not applicable.

(Notes on premise of a going concern)

Not applicable.

3. Supplemental Information

(1) Sales of major products and merchandise Consolidated

(Thousands of yen)

	First six months of the previous fiscal year (from April 1, 2023 to September 30, 2023)	First six months of the current fiscal year (from April 1, 2024 to September 30, 2024)	Percentage change (%)
1. Ethical Pharmaceuticals Business	23,900,997	28,544,724	19.4
Asacol	10,097,551	11,254,403	11.5
DIFICLIR	6,545,802	9,889,515	51.1
Entocort	2,447,326	2,630,933	7.5
Acofide	1,522,454	1,526,589	0.3
Other	3,287,862	3,243,282	(1.4)
2. Consumer Healthcare Business	12,700,282	13,802,248	8.7
Hepalyse range	5,190,313	5,877,864	13.2
Chondroitin range	2,862,851	2,825,598	(1.3)
WithOne range	612,894	722,551	17.9
Other	4,034,223	4,376,234	8.5
3. Other Business	77,124	75,645	(1.9)
Total	36,678,404	42,422,617	15.7

(2) Status of pipeline of new drugs

I. Domestic

As of November 6, 2024

Stage	Development Code/ Generic Name	Development	Indications	Classification	Origin
NDA approved	ZG-801/Patiromer Sorbitex Calcium	Zeria	Hyperkalemia	Potassium binder	In-licensed
Phase III	Z-338/Acotiamide	Zeria	Pediatric functional dyspepsia	Upper gastrointestinal motility modulator	Original
Phase II	ZG-802/Acotiamide	Zeria	Underactive bladder	Lower urinary tract function modulator	Original

II. Overseas

Stage	Development Code/ Generic Name	Development	Indications	Classification	Origin
NDA approved (Peru, Guatemala)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
NDA filed (Vietnam)	Z-338/Acotiamide	Pharmaceutical Joint Stock Company of February 3rd	Functional dyspepsia	Upper gastrointestinal motility modulator	Original
NDA filed (Singapore)	Z-338/Acotiamide	United Italian Trading Corporation Pte. Ltd.	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
NDA filed (Colombia, Costa Rica, Panama, Nicaragua)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
Phase III (Europe, United States, Canada)	Z-338/Acotiamide	Agastra-Lab s.r.l.	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)

Launched in Overseas

Launch Date	Development Code/ Generic Name	Development	Indications	Classification	Origin
March–May 2024 (Ecuador, Dominican Republic, Honduras, El Salvador, Chile)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
September 2024 (Thailand)	Z-338/Acotiamide	Meiji Seika Pharma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)